Amneal Pharmaceuticals, Inc. Press Releases https://investors.amneal.com/generated by Q4Tue, 10 Mar 2026 16:55:30 -0400Copyright Q4 Inc. All rights reserved.Amneal to Participate in Upcoming Investor Conferenced853c4c2-8f01-418e-a9b5-ffeeff9eea3dhttps://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-to-Participate-in-Upcoming-Investor-Conference/default.aspxThu, 05 Mar 2026 16:05:00 -0500Amneal Reports Fourth Quarter and Full Year 2025 Financial Results2fe08f49-c44a-4fff-a0df-de02153bbb59https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspxFri, 27 Feb 2026 06:00:00 -0500Amneal Pharmaceuticals Added to S&P SmallCap 600® Index3146881e-d1a0-44a1-a92d-24f670f54c60https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Pharmaceuticals-Added-to-SP-SmallCap-600-Index/default.aspxWed, 28 Jan 2026 16:05:00 -0500Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026b6d962c7-1fd1-44e2-a414-05fc2f43a4c2https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-to-Report-Fourth-Quarter-and-Full-Year-2025-Results-on-February-27-2026/default.aspxTue, 27 Jan 2026 08:00:00 -0500Amneal Unveils Bold New Brand to Reimagine What’s Possible in Making Medicine Accessible for All43db2433-128f-46b3-880d-fefaf4756fe9https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Unveils-Bold-New-Brand-to-Reimagine-Whats-Possible-in-Making-Medicine-Accessible-for-All-2026-PkNbhmgDo5/default.aspxMon, 12 Jan 2026 16:00:00 -0500Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®cb247b54-da0b-4c91-a4bc-985f468eea77https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Announces-FDA-Approval-of-Denosumab-Biosimilars-Referencing-Prolia-and-XGEVA/default.aspxMon, 22 Dec 2025 16:01:00 -0500Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals3187687f-b106-4255-b5c3-c73b9443fb80https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Receives-U-S--FDA-Approval-for-Epinephrine-Injection-in-Single--and-Multi-Dose-Vials-for-U-S--Hospitals/default.aspxTue, 09 Dec 2025 16:01:00 -0500Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease923c5ed3-8fec-4011-aa74-c669eb39c0b0https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Announces-Positive-Interim-Phase-4-ELEVATE-PD-Results-With-CREXONT-for-Parkinsons-Disease/default.aspxFri, 05 Dec 2025 08:00:00 -0500Amneal to Participate in Upcoming Investor Conferences60dde5ad-06d4-4ef5-8c5d-2fecf1351b35https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-to-Participate-in-Upcoming-Investor-Conferences/default.aspxTue, 02 Dec 2025 08:00:00 -0500Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol22086db4-e369-4512-895a-653354ec399chttps://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Receives-U-S--FDA-Approval-for-Albuterol-Sulfate-Inhalation-Aerosol/default.aspxTue, 02 Dec 2025 08:00:00 -0500